We expressed KLC2-WT, R312W, and L523I MT in CML cells in vitro and in vivo to examine the impact of KLC2 mutations in CML-to-CML-BP transformation. This evidence concerns the gene KLC2 and chronic myelogenous leukemia, BCR-ABL1 positive.